Background RTX is used off-label in several neurological inflammatory diseases in adults
children patients. We conducted a study to assess indications and safety of rituximab (RTX) …

Background: Early and effective treatment of central nervous system (CNS) inflammatory
disorders is vital to reduce neurologic morbidity and improve long-term outcomes in affected …

Objective To investigate the immunologic impact of a single cycle of rituximab (RTX) in
children and adolescents with immune-mediated disorders, we evaluated B cells and …

Objective: To assess the utility and safety of rituximab in pediatric autoimmune and
inflammatory disorders of the CNS. Methods: Multicenter retrospective study. Results: A total …

Background Rituximab (RTX) resistance or early B-cells repopulation were observed in
children but only few publications reported the use of Obinutuzumab and no …

Purpose Rituximab is increasingly used as a second-line treatment of neuroinflammatory
disorders to improve clinical outcomes in cases refractory to conventional immunotherapy …

Objective: To assess the effectiveness and safety of rituximab in Chinese children with
autoimmune diseases of the nervous system. Method: An ambispective cohort study …

Background and objectives To determine the real-world data regarding the use of Rituximab
(RTX) in neuroinflammatory disorders (NIDS) and assess the outcomes following RTX …

Rituximab is a widely used B-cell-depleting monoclonal antibody. It is unlicensed for use in
neurological disorders and there are no treatment guidelines. However, as a rapidly acting …

Background Rituximab is a B-cell therapy used off-label to reduce relapses in adult
demyelinating diseases. There is limited knowledge of its clinical use in pediatric …